Monograph Details
|
|
Infections & Infestations
> Bacterial infections
|
|
ZITHROMAX INJECTION |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Macrolide (azalide). |
| Generic Name |
|
Azithromycin 500mg/vial; for IV infusion after reconstitution and dilution. |
| Also |
• ZITHROMAX
• ZITHROMAX ORAL SUSP
• ZITHROMAX PACKETS
|
| Indications |
|
Susceptible infections including community-acquired pneumonia, pelvic inflammatory disease (PID). |
| Children |
|
<16yrs: not recommended. |
| Adults |
|
Give by IV infusion 1mg/mL over 3 hrs or 2mg/mL over 1hr. ≥16yrs: Pneumonia: 500mg once daily for at least 2 days, switch to 500mg orally once daily, for a total of 7–10 days combined therapy. PID: 500mg once daily for 1–2 days, switch to 250mg orally once daily for a total of 7 days combined therapy. |
| Contraindications |
|
Ketolide or related allergy. |
| Precautions |
|
Pneumonia: oral treatment is for mild, community-acquired cases suitable for outpatient therapy only. Hepatic or renal impairment. Hypersensitivity reactions may recur after initial successful symptomatic treatment. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Avoid concomitant aluminum- or magnesium-containing antacids. Monitor digoxin, cyclosporine, ergots, hexobarbital, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir. |
| Adverse Reactions |
|
GI upset, abdominal pain, rash, chest pain; rare: allergy (eg, angioedema, cholestatic jaundice). |
| How Supplied |
Tabs—30
Z-Pak (6 x 250mg tabs)—3
Tri-Pak (3 x 500mg tabs)—3
Susp 100mg/5mL—15mL
200mg/5mL—15mL, 22.5mL, 30mL
Single Dose Packets—3, 10
Inj (500mg vials)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
